Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK-SPARE 1 baricitinib in new-onset polymyalgia rheumatica
2020-005081-34Phase 3Active
- Sponsor
- Medical University of Vienna
- Start
- May 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Baricitinib plus rapidly tapered glucocorticoid with Placebo plus rapidly tapered glucocorticoid (2 arms). Primary endpoint: Proportion of subjects in glucocorticoid-free remission at week 16. Started May 2021; status: active.
02
Drugs
baricitinib
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2020-005081-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005081-34.